Methods and compositions for radioprotection and mitigation of radiation-induced injury using kinase inhibitors
OwnerAlbert Assadinventor
Life of this patent
Estimating the term…
Abstract
The present application provides methods of treating a disease or disorder related to radiation exposure in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits kinases such as JAK1, JAK1 and JAK2, or PI3Kδ.
Claims38
A method of treating or preventing a disease or disorder related to radiation exposure in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits JAK1, JAK1 and JAK2, or PI3Kδ.
-9. (canceled)
-17. (canceled)
-24. (canceled)
-33. (canceled)
-44. (canceled)
-59. (canceled)
-62. (canceled)
-70. (canceled)
-74. (canceled)
(canceled)
-82. (canceled)
-85. (canceled)
-107. (canceled)
A method of increasing the survival rate of a patient exposed to radiation, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits JAK1, JAK1 and JAK2, or PI3Kδ.
-120. (canceled)
A kit comprising:
- (a) ruxolitinib, povorcitinib, itacitinib, parsaclisib, or a pharmaceutically acceptable salt of any of the aforementioned;
- and (b) instructions for using the ruxolitinib, povorcitinib, itacitinib, parsaclisib, or a pharmaceutically acceptable salt of any of the aforementioned for treating or preventing acute radiation syndrome of a patient.
-123. (canceled)
Dependencies are inferred from the claim text.